To establish the genotype-phenotype correlations of various CYP1B1 (human cytochrome P450) mutations in patients in India with primary congenital glaucoma (PCG).
P rimary congenital glaucoma (PCG) is a severe form of childhood blindness caused by developmental defect(s) in the trabecular meshwork and anterior chamber angle of the eye. These abnormalities cause the obstruction of outflow of aqueous humor, which in turn results in raised intraocular pressure (IOP). If PCG is left untreated, it results in optic nerve damage and subsequent loss of vision. It is usually seen in the age group of birth to 3 years. Clinical manifestations include elevated IOP, enlargement of the globe, edema, and opacification of the cornea, with rupture of Descemet's membrane, photophobia, blepharospasm, anomalously deep anterior chamber and excessive tearing. It is mostly inherited as an autosomal recessive disorder and, in a few cases, parent-tochild transmission (pseudodominance) of the disease also occurs.
1 Inbred populations show a higher incidence of the disease. It is seen in 1 in 10,000 cases in the West, 2 1 in 3300 in the state of Andhra Pradesh in India, 3 1 in 2500 in Saudi Arabia, 4 and 1 in 2500 in the Slovakian Romany population. 5 Using linkage analysis, PCG (gene symbol GLC3) has been mapped to three different loci, GLC3A (at 2p21), GLC3B (at 1p36), and GLC3C (at 14q24.3) (Stoilov IR, et al. IOVS 2002; 43 :ARVO E-Abstract 3015). 6, 7 Although these three loci have been linked to PCG, only the gene, CYP1B1 (Online Mendelian Inheritance in Man [OMIM] 601771, a member of the cytochrome P450 supergene family) at the GLC3A locus has been identified to date.
Approximately 45 mutations in the coding region (exons II and III) of this gene (GenBank accession no. U56438; http:// www.ncbi.nlm.nih.gov/Genbank; provided in the public domain by the National Center for Biotechnology Information, Bethesda, MD) have now been implicated in the pathogenesis of PCG. These include deletion, insertion, point mutation, missense, nonsense, frameshift, and chain terminator mutations. Membrane-bound cytochromes such as CYP1B1 have a transmembrane domain, which is located at the amino terminal end of the molecule. This is followed by a proline rich "hinge" region, which permits flexibility between the membrane-spanning domain and the cytoplasmic portion of the molecule. The carboxyl terminal region has highly conserved core structures (CCSs) and is required for the proper heme-binding ability of the CYP1B1 molecule. Those mutations at the N-terminus hinge region or C terminus CCSs are expected to interfere with fundamental properties of the cytochrome P450 molecule, such as proper folding, heme binding, and formation of stable hemoprotein complex, substrate accommodation, and interaction with the redox partner, and to decrease significantly the enzyme's metabolism. 1, 8, 9 Frameshift mutations causing premature stop codons in the open reading frames would result in functional null alleles. 1, 10 Several CYP1B1 mutations would cause conformational changes in the DNA which in turn affect the structure function relationship of CYP1B1. 11, 12 This conformational change could result in disease manifestation. Though a wide spectrum of the aforementioned mutations in CYP1B1 were reported in various ethnic populations, 1,10 -27 scant information is available on the genotype-phenotype correlations of this devastating childhood blinding disorder.
PCG from 138 pedigrees and reported six distinct CYP1B1 mutations from 45 patients with PCG from India. 10, 27 These include four novel mutations: ins 376A or Ter@223(frameshift), P193L, E229K, R390C, and two known mutations, G61E and R368H.
Herein, we describe the results of genotype-phenotype correlations of 43 Indian patients with PCG, its implications in disease prognoses and the de novo mutation identified. In addition, we report the severity index developed for grading various congenital glaucoma phenotypes that occur in India.
METHODS

Selection and Evaluation of Study Subjects
This investigation followed the tenets of the Declaration of Helsinki. The Institute's Ethics Committee approved the research. After obtaining informed consent, both consanguineous and nonconsanguineous subjects (n ϭ 146) from 138 pedigrees were recruited. All subjects (both familial and sporadic cases) were clinically evaluated by a glaucoma specialist (AKM) and diagnosed with PCG by slit lamp biomicroscopy, gonioscopy, measurement of IOP, and perimetry wherever possible. About half (51.5%) of the families recruited were of a nonconsanguineous group; sporadic cases accounted for 80%. All subjects enrolled were followed up for several years, and samples were collected over 2 years in the Children's Eye Care Centre at the Institute. The various clinical parameters of PCG subjects and the ranges observed are given in Table 1 . The quantitative clinical data of PCG study subjects are given in Table 2 .
Mutation Screening of CYP1B1 Gene and Direct Sequencing
Genomic DNA was prepared from peripheral lymphocytes. The coding regions (1.6 Kb) spanning exons, II and III of CYP1B1 gene 28 (GenBank accession no. U56438) were amplified from genomic DNA of patients and control samples using three sets of primers as described earlier. 21 The amplicons were sequenced directly, and the patient and control sequences were compared, to identify the mutations.
PCR-RFLP Analysis
All six mutations identified earlier resulted in restriction site changes and, based on this polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method were developed 10, 27 for further screening of the samples. All the PCR-RFLP-positive samples were sequenced again to confirm the respective mutations using an automated DNA sequencer (Prism 3700; Applied Biosystems, Foster City, CA) using dye terminator chemistry sequencing (Big Dye; Applied Biosystems). Seventy healthy volunteers without any history of eye disorders were used as normal control subjects.
Statistical Analysis
Because there was asymmetric phenotype between both eyes of several patients analyzed, severe phenotype exhibited in at least one eye was considered for calculating the percentage of severity of disease against each mutation. Correlation between severity and prognosis was estimated using Spearman's rank correlation coefficient, and P Ͻ 0.05 was considered to be statistically significant.
Microsatellite Analysis
Microsatellite analysis was performed to assess paternity in pedigree 0017 using 11 highly polymorphic short tandem repeat (STR) markers from the X-and Y-chromosomes and from the autosomes. The markers used were from a PCR amplification kit (AmpFlSTR Profiler Plus; Applied Biosystems, Foster City, CA). This kit coamplifies the repeat regions of the following 11 short tandem repeat loci and their respective chromosomal locations are given in parentheses: D3S1358 (3p), vWA (12p12-pter), FGA (4q28), D8S1179 (8), D21S11 (21), D18S51 (18q21.3), D5S818 (5q21-31), D13S317 (13q22-31), D7S820 (7q11. [21] [22] , and (X:p22.1-22.3; Y:p11.2). A segment of the X-Y homologous gene amelogenin was also amplified for gender identification. One primer of each locus-specific primer pair was labeled with either the 5-FAM, JOE, or NED NHS-ester dye, which was detected as blue, green, and yellow, respectively, on the sequencer (Prism 3700; Applied Biosystems).
RESULTS
Identification of De Novo Mutation
It is notable that de novo mutation was identified in one of the families. Mutation in family 0017 was confirmed by sequencing, and cosegregation of mutant alleles with disease phenotype was ascertained by PCR-RFLP analysis (Fig. 1 ). An interesting instance was observed in family 0017, in which the affected male child (proband-II.1) was homozygous for R368H, whereas their mother (I.2) was heterozygous (carrier) for the same mutation. No sequence change was detected in the father (I.1), after several rounds of sequencing and PCR-RFLP analyses. He was found homozygous for the wild-type allele (normal) and the proband (II.1) had both carrier (II.2) and normal (II.3) siblings. Usually, for the manifestation of an autosomal recessive disease, both parents are expected to be carriers, but in this family only one of the parents (the mother, II.2) was found to be a carrier, and the first male child (proband II.1) was affected by PCG. Hence, we reasoned that the absence of mutation in the father could be due to nonpaternity or occurrence of paternal de novo mutation in the germline.
A similar instance of a paternal de novo homozygous germline mutation (G365W) was reported in an American family. 11 Their line of evidence also corroborates our findings. Paternity in this nonconsanguineous family was established by analyzing 11 highly polymorphic short tandem repeat (STR) markers (AmpFlSTR Profiler Plus Loci Kit; applied Biosystems) from the X and Y-chromosomes and from the autosomes (data not shown). For the Y-linked markers, the father and affected son (proband II.2) shared an identical haplotype, whereas, for the X-linked markers, the father and daughter shared another haplotype. Also, none of the autosomal markers showed any evidence of incompatibility in this pedigree. Therefore, no evidence for nonpaternity was found by our investigation. Moreover, the genomic DNA used for screening was obtained from peripheral leukocytes; hence, we interpreted this as a case of de novo mutation in the germline.
Severity Index for Grading PCG
Several cases of PCG with varying severity and manifestations have been identified in India. Hence, a severity index was constructed for grading various phenotypes. The phenotypes were graded from normal to severe, using the clinical parameters given in Table 3 . A phenotype was graded "very severe" when the last recorded vision ranged between less than 20/400 and no percep- Table 4 .
Genotype-Phenotype Correlations
By direct sequencing and PCR-RFLP methods six distinct CYP1B1 mutations were identified in 43 Indian patients with PCG. 10, 27 The respective genotype-phenotype correlations are shown in Table 5 . The six mutations identified comprise of four novel mutations: ins 376A or Ter@223 (frameshift), P193L, E229K, R390C, and two known mutations, G61E and R368H. All these patients had bilateral PCG. The prognosis of the disease was assessed for each patient based on his or her last recorded vision. The prognosis was graded into four categories: good, fair, poor, and very poor.
Depending on the combination of alleles, the genotypephenotype correlations varied ( Table 5 ). The worst phenotype was seen with frameshift mutation (0004p and 0004s) followed by R390C homozygous mutation (Table 5 ). All the patients with R390C homozygous mutation (0005f, 0012p, 0012s, 0018p, and 0092p) showed very severe phenotype and very poor prognosis compared with heterozygous mutation (0005p). Of all the mutations identified herein, the predominant one was R368H, which appeared in 25 patients. Six patients had the R390C mutation, followed by E229K, five; P193L, four; G61E, three; and frameshift, two (Table 4) . With all mutations, severe phenotypes were observed in at least one eye of the patients. The percentages of severe phenotypes seen in at least one eye against various mutations were frameshift, 100%, G61E, 66.7%; P193L, 62.5%; E229K, 80%; R368H, 72%; and R390C, 83.3% (Table 4 ). All patients with frameshift and G61E had homozygous mutations, whereas all E229K-bearing patients were heterozygous. Patients with P193L, R368H, and R390C had both homozygous and heterozygous mutations. Thirty-two percent of patients with the R368H mutation showed asymmetric phenotypes between eyes (Table 5) . Good correlation was found between the severity and prognosis of the disorder (r ϭ 0.976; P Ͻ 0.0001).
DISCUSSION
We reported the direct association of CYP1B1 mutations with PCG phenotypes from India. 10 Subsequently, in the current study, we screened by direct sequencing and PCR-RFLP analyses a large PCG cohort (146 subjects from 138 pedigrees) and identified six distinct mutations in 45 patients. We also found R368H to be the predominant mutation causing PCG in India. 27 This allele was earlier rarely reported from Middle East and Brazil, 17, 22 but in India 16.2% of the patients screened had the mutation. 27 This indicates that the mutation frequency varies, depending on the geographical location as well as ethnic background. Though a spectrum of CYP1B1 mutations from various ethnic backgrounds 1,10 -27 have been implicated in the pathogenesis of PCG, only a very few studies have reported genotype-phenotype correlations. 21, 22 In this investigation, we describe the genotype-phenotype correlations of 43 patients and their prognoses. Although PCG with varying phenotypes have been identified, this is first severity index for grading the various PCG phenotypes that has been developed. It enables grading of PCG from normal to very severe phenotypes (Table 3). Severe phenotypes were associated with all six mutations described in this study, but the percentage of severity varied with each mutation. For the different mutations, the associated percentages of severe phenotypes in at least one eye of the patient were: G61E, 66.7%; P193L, 62.5%; E229K, 80%; R368H, 72%; R390C, 83.3%; and frameshift, 100% (Table 4) .
Of all the mutations studied, frameshift and R390C homozygous mutations were found to be associated with very severe phenotypes and very poor prognoses. Even though multiple surgical interventions were performed in two patients (0004p and 0004s) with frameshift mutations, both eventually became blind (Table 5 ). This could be because the frameshift mutation resulted in a functional null allele lacking all domains of CYP1B1. 10 Whether surgery was performed at 1 week or 4 weeks, all five patients (0005f, 0012p, 0012s, 0018p, and 0092p) with R390C homozygous mutations exhibited uniformly very severe phenotypes and had very poor prognoses (Table 5 ). This indicates that probably clinical interventions in these patients had limited value. However, another study in a group of patients shows that early and prompt surgical interventions resulted in better prognosis. 29, 30 Probably these patients had mutations that were different from those reported in the current study, and they may be less severe. This study gives the genotype-phenotype correlations of a large number of patients with PCG (25 patients) with R368H mutation. It was found that 72% of them had severe phenotype in at least one eye. Both R368H and R390C residues are highly conserved across various members of the cytochrome P450 superfamily (data not shown). These residues map to helix K, which is one of the highly conserved core structures (CCSs) and is thought to be involved in proper protein folding and in active heme binding. Therefore, these mutations could lead to severe phenotypes. 1, 10, 17 The highly conserved glycine residue at position 61 is in a left-handed helical conformation and is in a very unique position, where the peptide chain takes a sharp turn. 10 The G61E mutation 12 is adjacent to the N-terminal proline-rich region of CYP1B1, is also likely to affect proper protein function, and hence results in disease manifestation. The proline-prolineglycine-proline motif may serve to join the membrane-binding N terminus to the globular region of P450 protein. 13, 14, 18, 24 Mutations in the hinge region have been reported to interfere with the proper folding and heme-binding properties of cytochrome P450 molecules. 1, 8 It has been shown that this mutation significantly reduces the enzyme's metabolism.
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P193 and E229 amino acid (aa) residues are also conserved among various members of the cytochrome P450 superfamily. 10 Mutational analyses of CYP1B1 coding exons revealed homozygous mutations in 30 of 43 Indian patients described in this study. Two patients (0001 and 0035) showed compound heterozygous mutations, whereas in 11 patients, only single heterozygous mutations were detected. Because we could not identify the second mutation in 11 heterozygous patients, we conclude that it could be due to mutations in (1) CYP1B1 promoter or control region; (2) genes linked to other PCG loci such as GLC3B and GLC3C; (3) other glaucoma genes such as FOXC1 and MYOC, resulting in digenic inheritance; or (4) some other unknown genes causing glaucoma. Mutations in the forkhead transcription factor gene FOXC1 (formerly called FKHL7) could also contribute to the development of PCG. 31 Hence, it is possible that PCG can be due to mutations in multiple genes (such as CYP1B1 and FOXC1, CYP1B1 and MYOC, genes linked to GLC3B and C or some other loci). Digenic inheritance in glaucoma has been shown recently in two instances, such as in early-onset glaucoma in humans and also in mice with PCG. 32, 33 CYP1B1 and MYOC mutations were identified in early-onset glaucoma in humans, 32 whereas mutations in CYP1B1 and FOXC1 were detected in mice with PCG. 34 This points to the fact that mutations in genes other than CYP1B1 can cause PCG, because all these genes could contribute to the development of anterior chamber angle. PCG is caused by unknown developmental defect(s) in trabecular meshwork and anterior chamber angle of the eye.
1 Angle structures are mainly derived from the neural crest cells; hence, defects in genes expressed in neural crest cells could also contribute to PCG.
The genotype/phenotype correlation varies, depending on the combination of alleles. The PCG phenotypes associated with heterozygous mutations varied from mild to severe, and this variation could be due to the various combinations of alleles (Table 5 ). The phenotypic heterogeneity of this disorder seen in India could reflect the underlying genetic heterogeneity of the disorder. We screened 146 well-characterized patients with PCG for CYP1B1 mutations and detected mutations in only 45 of them. This indicates that mutations in non-CYP1B1 genes in other loci could also cause this disorder and also highlights the genetic complexity of PCG in India. This is the first study to describe the genotype-phenotype correlations of a large number of patients with PCG. A severity index for grading congenital glaucoma has been developed for the first time. This is the second report demonstrating the occurrence of de novo mutation in CYP1B1 gene causing PCG. This study also indicates that probably genotype could be used as an indicator in predicting the prognosis of the disease-for instance, in the case of frameshift and R390C mutations described in this study. Because PCG results in high life-long morbidity, genetic counseling and rehabilitation of the patient are very important in reducing the burden of the afflicted family, and may improve the quality of life. An integrated management of PCG using genetic approach along with medical, surgical, and rehabil- itation interventions could yield better results in tackling this devastating blinding disease of childhood. In sum, the data derived from this study could be used as an added clinical tool in managing the disease better. Establishing genotype-phenotype correlations of PCG may aid in knowing the prognosis of the disease, in guiding therapy and in counseling the afflicted families. Therefore, further studies involving large number of families from various ethnic backgrounds would be required in establishing the genotype-phenotype correlations of this blinding disorder in children.
Furthermore, the molecular consequences of the mutations found to date, provide a framework for genotype-phenotype correlation and suggest future studies in light of results of investigation of normal and mutant CYP1B1.
